Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VL-2397 vs Standard of Care for Invasive Aspergillosis
NCT03327727Phase 2Terminated
- Sponsor
- Vical Incorporated
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Peptides, Covalent Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of GR-2397 in invasive aspergillosis (IA), sponsored by Vical Incorporated. Started Feb 2018; status: terminated.
02
Drugs
GR-2397
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT03327727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03327727.